Jon Congleton Insider Profile
11 Followers
Jon Congleton, Director at Immunic, holds ― shares in Immunic (Ticker: IMUX), holds 614.32K shares in Mineralys Therapeutics, Inc. (Ticker: MLYS), holds ― shares in Avalyn Pharma Inc (Ticker: AVLN). Most recently, Jon Congleton ― shares of Immunic on ― for an estimated value of ―.
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
+22.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jon Congleton holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Nov 27, 2023 - Nov 27, 2024
Return:+103.50%
The most profitable trade made by Jon Congleton
Jon Congleton's Trading History
Immunic
―
Director
―
―
Mineralys Therapeutics, Inc.
Jun 30, 2026
CEO, Director
Uninformative Sell
1.96M
$17.33M
Avalyn Pharma Inc
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Jon Congleton's performance on stock
You May Also Like
Jon Congleton insider profile FAQ
What is the percentage of profitable transactions made by Jon Congleton?
The percentage of profitable transactions made by Jon Congleton is 40%.
What is the average return per transaction made by Jon Congleton?
The average return per transaction made by Jon Congleton is 22.70%.
What stocks does Jon Congleton hold?
Jon Congleton holds: IMUX, MLYS, AVLN stocks.
What was Jon Congleton’s latest transaction?
Jon Congleton latest transaction was an Uninformative Buy of ―.
What was Jon Congleton's most profitable transaction?
Jon Congleton’s most profitable transaction was an Informative Buy of MLYS stock on November 27, 2023. The return on the trade was 103.50%.
What is Jon Congleton's role in Immunic?
Jon Congleton's role in Immunic is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.